Jessica L. Heath

ORCID: 0000-0003-1771-2242
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Childhood Cancer Survivors' Quality of Life
  • Epigenetics and DNA Methylation
  • Nuclear Structure and Function
  • Genomics and Chromatin Dynamics
  • Erythrocyte Function and Pathophysiology
  • Cancer-related gene regulation
  • Protein Degradation and Inhibitors
  • Patient-Provider Communication in Healthcare
  • Iron Metabolism and Disorders
  • RNA modifications and cancer
  • Parvovirus B19 Infection Studies
  • Cancer-related molecular mechanisms research
  • Adolescent and Pediatric Healthcare
  • Chronic Myeloid Leukemia Treatments
  • MicroRNA in disease regulation
  • Cardiac Imaging and Diagnostics
  • Patient Satisfaction in Healthcare
  • Vascular Tumors and Angiosarcomas
  • Mental Health via Writing
  • Hospital Admissions and Outcomes
  • Ethics and Legal Issues in Pediatric Healthcare
  • Immunotherapy and Immune Responses
  • Management and Marketing Education

University of Vermont Children’s Hospital
2020-2024

University of Vermont
2017-2022

Vermont Cancer Support Network
2020

Duke Medical Center
2010-2014

Duke University
2013

Allen Hospital
2011-2012

University of Vermont Medical Center
2011-2012

Albany Medical Center Hospital
2007

Carolinas Medical Center
2007

The ubiquitously expressed phosphatidylinositol binding clathrin assembly (PICALM) protein associates with the plasma membrane, binds clathrin, and plays a role in clathrin-mediated endocytosis. Alterations of human PICALM gene are present aggressive hematopoietic malignancies, genome-wide association studies have recently linked locus to late-onset Alzheimer's disease. Inactivating hypomorphic Picalm mutations mice cause different degrees severity anemia, abnormal iron metabolism, growth...

10.1371/journal.pone.0044252 article EN cc-by PLoS ONE 2012-08-30

Inactivation of the tumor suppressor gene encoding transcriptional regulator Ikaros (IKZF1) is a hallmark BCR-ABL1+ precursor B cell acute lymphoblastic leukemia (pre-B ALL). However, mechanisms by which functions as in pre-B ALL remain poorly understood. Here, we analyzed mouse model together with new inducible expression wild-type IKZF1 mutant human ALL. We performed integrated genome-wide chromatin and analyses identified target genes ALL, revealing novel conserved pathways associated...

10.1084/jem.20160049 article EN cc-by-nc-sa The Journal of Experimental Medicine 2017-02-11

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a reactive, proliferative disorder of the immune system resulting in lymphohistiocytic proliferation, hemophagocytosis, and cytokine dysregulation. The most common infectious trigger sHLH Epstein-Barr virus (EBV-HLH). Current treatment protocols for EBV-HLH have cure rate approximately 75%; however, there are significant toxicities associated with these therapies. We present two patients who experienced spontaneous resolution their...

10.1002/pbc.22618 article EN Pediatric Blood & Cancer 2010-05-27

Histiocytic sarcoma (HS) is a malignant tumor composed of proliferating cells histiocytic origin. True HS exceedingly rare, particularly in pediatric patients. These tumors are frequently aggressive, and outcome for patients with has traditionally been poor. There currently no consensus on the optimal management these tumors, literature consisting largely case reports small series utilizing wide variety therapies. We describe an 8-year-old female who was successfully treated abbreviated...

10.1002/pbc.25100 article EN Pediatric Blood & Cancer 2014-05-29

Abstract Advanced small cell carcinoma of the ovary (FIGO stage III or IV) is a rare and usually lethal tumor seen in adolescents young women. In pediatric patients with advanced disease, there have been only two case reports successful therapy, we report third patient, diagnosed at 17 years age, an abdominal mass metastatic disease to regional distant lymph nodes, who was successfully treated surgery intensive multi‐agent chemotherapy. Imatinib, thalidomide, celecoxib were also administered...

10.1002/pbc.21333 article EN Pediatric Blood & Cancer 2007-10-03

Adolescents and young adults (AYAs; age 15-39 years) with cancer are under-represented in clinical trials because of patient, provider, institutional barriers. Health care technology is increasingly available to highly used among AYAs has the potential improve delivery. The COVID-19 pandemic forced institutions rapidly adopt novel approaches for enrollment monitoring patients on trials, many which have improving AYA trial participation overall. This consensus statement from Children's...

10.1200/op.21.00554 article EN JCO Oncology Practice 2021-12-14

Non-coding RNAs (ncRNAs) comprise a diverse class of non-protein coding transcripts that regulate critical cellular processes associated with cancer. Advances in RNA-sequencing (RNA-Seq) have led to the characterization non-coding RNA expression across different types human cancers. Through comprehensive RNA-Seq profiling, growing number studies demonstrate ncRNAs, including long (lncRNAs) and microRNAs (miRNA), play central roles progenitor B-cell Acute Lymphoblastic Leukemia (B-ALL)...

10.20944/preprints202102.0496.v1 preprint EN 2021-02-22

10.1016/j.exphem.2014.08.004 article EN publisher-specific-oa Experimental Hematology 2014-09-03

Disseminated cryptococcal infection is rarely reported in the setting of pediatric acute leukemia, despite immunocompromised state these patients. However, when present, disseminated poses treatment challenges and associated with significant morbidity mortality. Treatment invasive fungal disease a child leukemia requires delicate balance between antifungal antineoplastic therapy. This particularly important early course as both underlying overwhelming can be life threatening. We describe...

10.1097/mph.0b013e318236c502 article EN Journal of Pediatric Hematology/Oncology 2012-05-01

Cystic angiomatosis (CA) is a rare disease characterized by the proliferation of vascular and lymphatic channels lined single layer endothelial cells. CA may present with isolated skeletal or visceral disease. There no consensus for standard care in these patients, diverse regimens have been reported, including observation, surgery, radiation, variety medical therapies. We case multifocal, CA, treated close observation alone review literature. suggest that cases be safely followed without...

10.1097/mph.0000000000001750 article EN Journal of Pediatric Hematology/Oncology 2020-02-19

Central nervous system (CNS) chloromas are an exceedingly rare presentation of CNS relapse in acute lymphoblastic leukemia (ALL). We report a relapsed ALL patient who presented with 2 separate and cerebrospinal fluid lymphoblastocytosis, outline treatment plan systemic chemotherapy CNS-directed radiation therapy. A review the literature indicates that multiagent combined radiotherapy is effective, hematopoietic stem cell transplantation used half reported cases. conclude intensive therapy...

10.1097/mph.0000000000001085 article EN Journal of Pediatric Hematology/Oncology 2018-01-12

Polyethylene glycosylated (PEG)-asparaginase is a cornerstone of treatment for acute lymphoblastic leukemia (ALL), and effective administration associated with better outcomes. PEG-asparaginase uniphasic hypersensitivity reaction in ∼10% to 20% patients. We present 17-year-old male individual diagnosed very high-risk pre-B-ALL, who experienced protracted anaphylaxis 1 hour following his second dose. This type allergic has yet be described ALL patients treated PEG-asparaginase. Here, we...

10.1097/mph.0000000000001906 article EN Journal of Pediatric Hematology/Oncology 2020-08-18

Leukemia transformed by the CALM-AF10 chromosomal translocation is characterized a high incidence of extramedullary disease, central nervous system (CNS) relapse, and poor prognosis. Invasion compartment CNS requires leukemia cell migration out marrow adherence to cells local tissue. Cell adhesion are increasingly recognized as contributors development therapeutic response. These processes mediated variety cytokines, chemokines, their receptors, forming networks both secreted surface...

10.3389/fonc.2021.708915 article EN cc-by Frontiers in Oncology 2022-01-05

The concept of trust has been extensively studied within the field medicine. Yet, a list factors that clearly influence patients' is still under debate. Moreover, methodological approaches found in literature have reported to be lacking their assessments and measurements relationships medical although between patient provider proven increase adherence improve health outcomes. Hence, adding data this debate exploring reliable method explore construct relevant. This study collects new evidence...

10.1080/10410236.2022.2131973 article EN Health Communication 2022-10-10
Coming Soon ...